Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Capital Expenditures (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Capital Expenditures for 6 consecutive years, with $71000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures rose 277.5% year-over-year to $71000.0, compared with a TTM value of $71000.0 through Dec 2025, changed N/A, and an annual FY2025 reading of $71000.0, changed N/A over the prior year.
  • Capital Expenditures was $71000.0 for Q4 2025 at Puma Biotechnology, up from -$10000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $71000.0 in Q4 2025 and bottomed at -$51000.0 in Q2 2025.
  • Average Capital Expenditures over 3 years is $9111.1, with a median of $10000.0 recorded in 2024.
  • The sharpest move saw Capital Expenditures surged 300.0% in 2024, then tumbled 610.0% in 2025.
  • Year by year, Capital Expenditures stood at $26000.0 in 2023, then tumbled by 253.85% to -$40000.0 in 2024, then surged by 277.5% to $71000.0 in 2025.
  • Business Quant data shows Capital Expenditures for PBYI at $71000.0 in Q4 2025, -$10000.0 in Q3 2025, and -$51000.0 in Q2 2025.